Physician profile
Michael C Chabot
NPI 1588635353
$60,598.91
in general payments reported to CMS, 2019-2025
14 companies · $1,314 in 2025
The $1,314 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $15K · 2021: $16K · 2022: $4,497 · 2025: $1,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,250 · Food and Beverage: $63.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,250.00 |
| Food and Beverage | $63.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $58,005.18 | 2019-2022 | |
| Centinel Spine, LLC | $1,250.00 | 2025 | Prodisc L |
| Zimmer Biomet Holdings, INC. | $1,049.57 | 2019-2021 | |
| Elite Orthopedics, LLC | $103.69 | 2019 | |
| Depuy Synthes Sales INC. | $35.95 | 2019 | |
| Medtronic USA, INC. | $32.54 | 2019 | |
| Cerapedics INC. | $25.29 | 2025 | I-Factor Peptide Enhanced Bone Graft |
| Ebi, LLC | $19.34 | 2025 | Biomet Spinalpak Non-Invasive Spine Fusion Stimulator System |
| Orthofix Medical, INC. | $19.07 | 2025 | Cervical-Stim |
| Bioventus LLC | $17.73 | 2020 | |
| Endo Pharmaceuticals INC. | $15.42 | 2019 | |
| Arteriocyte Medical Systems, INC. | $13.96 | 2019 | |
| Horizon Therapeutics Plc | $11.17 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$891,014.84 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chabot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.